KISQALI vs SPRYCEL

Independent side-by-side comparison.

Rated against independent regulatory sources·Last updated August 21, 2026·How we rate

Possible drug interaction. KISQALI and SPRYCEL are different prescription medicines. Combining or switching between them can cause interactions — talk to a pharmacist or prescriber before making changes. This page is not medical advice.

Attribute	KISQALI	SPRYCEL
Rating	70/100	72/100
Pharmacy pays	—	~$839.19 /30
Type	RX	RX
Active ingredient	RIBOCICLIB SUCCINATE	DASATINIB
Manufacturer	Novartis	Bristol Myers Squibb
Dosage forms	Tablet	Tablet
Drug class	Kinase Inhibitor	Kinase Inhibitor
Boxed warning	None	None
Treats	Breast Neoplasms	Lymphoid Leukemia, Myeloid Leukemia

kisqali sprycel

Rating

70/100

72/100

Pharmacy pays

—

~$839.19 /30

Type

Active ingredient

RIBOCICLIB SUCCINATE

DASATINIB

Manufacturer

Novartis

Bristol Myers Squibb

Dosage forms

Tablet

Drug class

Kinase Inhibitor

Boxed warning

None

Treats

Breast Neoplasms

Lymphoid Leukemia, Myeloid Leukemia

Frequently asked questions

Which is better-rated, Kisqali or Sprycel?

By our independent rating, Sprycel scores higher — 3.6 vs 3.5 out of 5 for Kisqali. Ratings are based on FDA regulatory (recall-safety) data.

What is the difference between Kisqali and Sprycel?

Kisqali contains Ribociclib Succinate, while Sprycel contains Dasatinib — they have different active ingredients.

Ratings are based on FDA regulatory (recall-safety) data. This comparison is for general reference only — not medical advice. Always consult a licensed professional before choosing or switching a medication.